share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)

SC 13G/A：超过5%持股股东披露文件(修正)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
美股SEC公告 ·  2024/11/15 04:57

Moomoo AI 已提取核心信息

On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of 180 Life Sciences Corp. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 53,935 shares, representing 4.99% of the company's class of securities. This stake is held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The filing also stated that as of the date of the filing, Armistice Capital and Boyd ceased to be the beneficial owners of more than five percent of the class of securities. The Master Fund retains the right to receive dividends or proceeds from the sale of these securities. The filing was completed in accordance with the SEC's rules and regulations, and the information provided was certified as true and correct by Steven Boyd on November 14, 2024.
On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of 180 Life Sciences Corp. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 53,935 shares, representing 4.99% of the company's class of securities. This stake is held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The filing also stated that as of the date of the filing, Armistice Capital and Boyd ceased to be the beneficial owners of more than five percent of the class of securities. The Master Fund retains the right to receive dividends or proceeds from the sale of these securities. The filing was completed in accordance with the SEC's rules and regulations, and the information provided was certified as true and correct by Steven Boyd on November 14, 2024.
2024年9月30日，和其管理成员史蒂文·博伊德的停战资本公司向美国证券交易委员会提交了修订版13G/A表格，表示他们对180 Life Sciences Corp.普通股的持股情况发生变化。 文件披露，停战资本和博伊德分别对53,935股股票享有共同表决权和处置权，占公司证券类别的4.99%。 这一股权由由停战资本根据投资管理协议管理的主基金持有。 申报还声明，截至申报日，停战资本和博伊德不再是该类证券中超过五成的受益所有人。 主基金保留有权获得分红或出售这些证券的收益。 该申报根据美国证券交易委员会的规定和法规完成，并且所提供的信息已由史蒂文·博伊德于2024年11月14日签署确认属实。
2024年9月30日，和其管理成员史蒂文·博伊德的停战资本公司向美国证券交易委员会提交了修订版13G/A表格，表示他们对180 Life Sciences Corp.普通股的持股情况发生变化。 文件披露，停战资本和博伊德分别对53,935股股票享有共同表决权和处置权，占公司证券类别的4.99%。 这一股权由由停战资本根据投资管理协议管理的主基金持有。 申报还声明，截至申报日，停战资本和博伊德不再是该类证券中超过五成的受益所有人。 主基金保留有权获得分红或出售这些证券的收益。 该申报根据美国证券交易委员会的规定和法规完成，并且所提供的信息已由史蒂文·博伊德于2024年11月14日签署确认属实。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Channel Therapeutics
    CHRO
    -- 1.900
    泰坦制药
    TTNP
    -- 3.8350
    LakeShore Biopharma
    LSB
    -- 2.723
    Rigel Pharmaceuticals
    RIGL
    -- 20.130
    Veru Inc
    VERU
    -- 0.975

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    特朗普2.0机会预览：在总统上任前猜出市场赢家！